Investor Relations

Psychedelics Are a Viable Solution to Mental
Health Issues

We’re at the threshold of industry transformation, as the stigmas and regulations shaping both psychedelics and mental health are challenged for the better.

The pathway for the psychedelics industry is optimistic, primed by the success of the cannabis space and international news of decriminalization. Since the first steps taken by Oregon to decriminalize psilocybin and legalize psychedelic-assisted therapy, stocks have skyrocketed for psychedelic therapy organizations in North America and the UK.

Market Trends

Why Analysts Think the Mental Health Industry Is Ripe for Growth

MINDCURE’s research, technology, and psychedelic compounds can disrupt mental health care by offering new alternatives where solutions are desperately needed, particularly in regard to confronting addiction.

12,472 treatment facilities as of 2019

As of 2019, there were 12,472 registered mental health treatment facilities in the U.S., which could benefit from an interconnected digital therapeutics platform, such as iSTRYM4

U.S. $7 billion by 2025

Where the addiction treatment market is expected to hit U.S. $7 billion by 2025, MINDCURE is joining the estimated $42 billion market for ibogaine-assisted treatment5

Recent section 56 exemptions

Regulatory bodies are quickly adapting to the demand for patient access for psychedelic medicines. Recent exemptions are opening doors to psilocybin treatment and clinical trials for approved terminally-ill patients

MINDCURE Company Highlights

Why Invest?

MINDCURE is a diversified psychedelic research and technology company at the forefront of the mental health industry. With research into indications for psychedelic substances, nootropic and adaptogenic products, digital therapeutics technology, and integrative partnerships, MINDCURE is prepared to offer what others in the space cannot.

A proprietary technology platform that will generate near term revenue

A growing team of scientific experts in experimental medicine, integrative psychiatry, trauma, and regenerative medicine

Exciting partnerships amplifying our software platform & facilitating clinical research

Our Partners

Capitalization Summary

Issued and Outstanding

53,422,596

Warrants Outstanding

9,139,404

Options Outstanding

7,205,000

Fully Diluted

69,767,000

Stock Quote

Pricing delayed by 20 minutes.

Last Updated
--/--/---- --:-- --
Price
--
Volume
--
Change
--
% Change
--
Today’s Open
--
Previous Close
--
Intraday High
--
Intraday Low
--
52 Week High
--
52 Week Low
--

Stock Chart

Corporate
Directory

Head Office

MINDCURE Health Inc.
170, 422 Richards Street
Vancouver, BC
Canada V6B 2Z4

info@mindcure.com
888-593-8995
Legal Counsel

Farris LLP
25th Floor, 700 West Georgia St
Vancouver, BC
Canada V7Y 1B3

604-684-9151
Accountants

Davidson & Company LLP
Chartered Professional Accountants
1200–609 Granville Street, P.O. Box 10372
Vancouver, BC
Canada V7Y 1G6

604-687-0947
Transfer Agent

Computershare
510 Burrard St, 3rd Floor
Vancouver, BC
Canada V6C 3B9

604-661-9476
604-661-9401 (fax)
Marketing

Tarik Lebbadi

tlebbadi@mindcure.com
Partnerships

Daniel Herrera

dherrera@mindcure.com
Investor Relations & Communications

Teya Hastie

thastie@mindcure.com